NovoCure (NASDAQ:NVCR) Shares Down 5.3% – Should You Sell?

Posted by Brian Himes on Nov 11th, 2026

NovoCure Limited (NASDAQ:NVCR – Get Free Report) shares fell 5.3% on Monday. The company traded as low as $12.25 and last traded at $12.5750. Approximately 1,391,651 shares traded hands during mid-day trading, a decline of 17% from the average session volume of 1,681,598 shares. The stock had previously closed at $13.28.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Zacks Research raised shares of NovoCure from a “strong sell” rating to a “hold” rating in a research report on Friday, July 24th. Weiss Ratings cut shares of NovoCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 30th. Wells Fargo & Company dropped their price target on shares of NovoCure from $20.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Friday, October 30th. Ladenburg Thalmann & Co. Inc. boosted their target price on NovoCure from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, HC Wainwright set a $32.00 price target on NovoCure in a research note on Friday, July 24th. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $22.33.

View Our Latest Report on NovoCure

NovoCure Trading Up 1.5%

The company has a fifty day moving average of $15.18 and a two-hundred day moving average of $14.77. The company has a current ratio of 2.49, a quick ratio of 2.34 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -11.31 and a beta of 1.09.

NovoCure (NASDAQ:NVCR – Get Free Report) last announced its earnings results on Thursday, October 29th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.14. NovoCure had a negative return on equity of 35.81% and a negative net margin of 16.78%. The firm had revenue of $193.40 million during the quarter, compared to analysts’ expectations of $182.28 million. During the same quarter in the prior year, the business earned ($0.33) earnings per share. The company’s revenue was up 15.7% on a year-over-year basis. On average, research analysts expect that NovoCure Limited will post -1.09 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of NVCR. Quantinno Capital Management LP lifted its position in shares of NovoCure by 23.7% during the 1st quarter. Quantinno Capital Management LP now owns 2,487,376 shares of the medical equipment provider’s stock worth $27,112,000 after purchasing an additional 477,128 shares during the last quarter. Renaissance Technologies LLC grew its holdings in NovoCure by 11.8% in the 1st quarter. Renaissance Technologies LLC now owns 1,551,554 shares of the medical equipment provider’s stock valued at $16,912,000 after buying an additional 163,800 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in NovoCure by 27.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 960,056 shares of the medical equipment provider’s stock valued at $10,462,000 after buying an additional 207,913 shares during the last quarter. Ieq Capital LLC increased its position in NovoCure by 24.3% in the 3rd quarter. Ieq Capital LLC now owns 341,782 shares of the medical equipment provider’s stock worth $5,451,000 after buying an additional 66,821 shares during the period. Finally, Russell Investments Group Ltd. increased its position in NovoCure by 7.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 196,874 shares of the medical equipment provider’s stock worth $3,140,000 after buying an additional 14,358 shares during the period. Institutional investors and hedge funds own 84.61% of the company’s stock.

NovoCure Company Profile

(Get Free Report)

NovoCure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), a cancer treatment that uses wearable devices to deliver low-intensity electric fields intended to disrupt cancer cell division. Its products include Optune Gio and Optune Lua, which are used to treat certain cancers. The company is headquartered in Baar, Switzerland, and serves patients in markets across North America, Europe and Asia. NovoCure was founded in 2000 by Yoram Palti, a medical researcher who developed the TTFields approach.